Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Obesity Drug Coverage Should Not Be Required For ACA Plans, Cigna Tells CMS

Executive Summary

Insurer's concerns about the cost of covering drugs that could be used by large swaths of the population has contributed to their reluctance to pay for them, but in comments to the agency, drug firms, consumer advocates and medical professionals urged the Centers for Medicare and Medicaid Services to promote coverage in the commercial plans governed by the Affordable Care Act.

You may also be interested in...

Obesity Drug Coverage In ACA Plans May Expand With Shift In Treatment Classification Standard

Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.

Medicare Coverage For Lilly’s Tirzepatide Could Be ‘Unlocked’ With Heart Failure, Apnea Claims

The problem that obesity drugs are not covered by Medicare Part D might be alleviated if Lilly’s weight loss candidate is also cleared for indications that are reimbursed. Policy and treatment experts discuss the importance of proving obesity drugs can lower federal government health care spending during a recent discussion convened by the Institute for Clinical and Economic Review.

FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals

Health policy experts discuss ways Medicare coverage policy may evolve in the coming years and how efforts to smooth the transition between accelerated drug approvals and Medicare reimbursement decisions could play out.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts